NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative ...

NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative ...

Has The Controversy Around Falsified Alzheimer's Research Impacted The Path To Finding The Cure? Finding the cure to Alzheimer’s has confounded researchers for decades. As a disease, Alzheimer ...

In this Insight, NervGen Pharma president and CEO Paul Brennan details why plasticity is so important for the brain. Never miss a story ...

NervGen holds exclusive worldwide rights to NVG-291, a first-in-class therapeutic peptide targeting mechanisms that interfere with nervous system repair. NVG-291 is derived from the intracellular ...

In addition, Neil Klompas, a seasoned pharmaceutical executive with extensive experience in high-growth companies joined our Board subsequent to the end of the quarter. Cash and Investments: NervGen ...

So should NervGen Pharma ( CVE:NGEN) shareholders be worried about its cash burn? In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company ...

NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, reported its financial ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...